

# Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1

Steven W. Millward,<sup>†</sup> Ryan K. Henning,<sup>†</sup> Gabriel A. Kwong,<sup>‡</sup> Suresh Pitram,<sup>§</sup> Heather D. Agnew,<sup>§</sup> Kaycie M. Deyle,<sup>†</sup> Arundhati Nag,<sup>†</sup> Jason Hein,<sup>⊥,||</sup> Su Seong Lee,<sup>#</sup> Jaehong Lim,<sup>#</sup> Jessica A. Pfeilsticker,<sup>†</sup> K. Barry Sharpless,<sup>⊥</sup> and James R. Heath<sup>\*,†</sup>

<sup>†</sup>Nanosystems Biology Cancer Center, Division of Chemistry and Chemical Engineering, MC-127-72, California Institute of Technology, Pasadena, California 91125, United States

<sup>‡</sup>Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States


<sup>§</sup>Integrated Diagnostics, 6162 Bristol Parkway, Culver City, California 90230, United States

<sup>⊥</sup>Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

<sup>#</sup>Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, Singapore 138669

**S** Supporting Information

**ABSTRACT:** We describe the use of iterative in situ click chemistry to design an Akt-specific branched peptide triligand that is a drop-in replacement for monoclonal antibodies in multiple biochemical assays. Each peptide module in the branched structure makes unique contributions to affinity and/or specificity resulting in a 200 nM affinity ligand that efficiently immunoprecipitates Akt from cancer cell lysates and labels Akt in fixed cells. Our use of a small molecule to preinhibit Akt prior to screening resulted in low micromolar inhibitory potency and an allosteric mode of inhibition, which is evidenced through a series of competitive enzyme kinetic assays. To demonstrate the efficiency and selectivity of the protein-templated in situ click reaction, we developed a novel QPCR-based methodology that enabled a quantitative assessment of its yield. These results point to the potential for iterative in situ click chemistry to generate potent, synthetically accessible antibody replacements with novel inhibitory properties.



## INTRODUCTION

A critical bottleneck in the transition from a potential cancer biomarker to a clinical diagnostic tool is the availability of high-affinity, high-selectivity molecular entities to recognize and capture biomarkers from complex biological mixtures. Almost all current platforms employ antibodies as capture agents despite their high cost, poor stability,<sup>1,2</sup> and the batch-to-batch variability that often characterizes biologicals. Many antibodies are poorly characterized, and reports have called into question the high specificity that is a perceived hallmark of antibodies.<sup>3,4</sup> Developing protein capture agent approaches, such as phage display peptides<sup>5</sup> or nucleic acid aptamers, can potentially represent a powerful alternative to antibodies for certain diagnostic arrays.<sup>6,7</sup> However, the challenge of finding a general and robust approach to produce protein capture agents that match the performance of monoclonal antibodies remains daunting. An ideal antibody replacement would be synthetically facile, be stable to a range of thermal and chemical conditions, and display high affinity and specificity for the target of interest.

A high quality monoclonal antibody possesses a low-nanomolar affinity and high target specificity. Interestingly, structural and

genetic analyses of the antigen recognition surface have shown that the majority of the molecular diversity of the variable loops is contained in a single highly variable loop (CDR-H3).<sup>8</sup> In humans, this loop ranges in size from 1 to 35 residues (15 on average),<sup>9</sup> can adopt a wide range of structural conformations,<sup>10</sup> and is responsible for most of the interactions with the antigen molecule. The other five loops are significantly less diverse and adopt only a handful of conformations. This suggests that a carefully selected “anchor” peptide can dominate the mode and strength of a multiligand interaction. It also suggests that other peptide components, while providing only modest contributions to the total interaction energy, can supply important scaffolding features and specificity elements. Analogously, the iterative in situ click chemistry approach utilized here begins with an initial short-chain anchor peptide and then proceeds by adding additional, covalently coupled peptide branches via a process that is promoted by the target protein. The specificity and inhibitory

**Received:** July 11, 2011

**Published:** September 30, 2011

potency of the original anchor are augmented in the final multiligand by the peripheral peptide branches.

We recently reported on the technique of iterative in situ click chemistry for the production of a triligand capture agent against the model protein carbonic anhydrase II (CAII).<sup>11</sup> The approach built upon the method of in situ click chemistry,<sup>12</sup> which is a technique in which a small molecule enzymatic inhibitor is separated into two moieties, each of which is then expanded into a small library, one containing acetylene functionalities and the other containing azide groups. The enzyme itself then assembles the 'best fit' inhibitor from these library components by selectively promoting the 1,3-dipolar cycloaddition between the acetylene and azide groups to form a triazole linkage (the 'click' reaction). The enzyme promotes the click reaction only between those library components that bind to the protein in just the right orientation. The resultant inhibitor can exhibit far superior affinity characteristics relative to the initial inhibitor that formed the basis of the two libraries.<sup>13,14</sup> Iterative in situ click chemistry extends this concept to enable the discovery of multiligand protein capture agents, and it has several advantages. First, structural information about the protein target is replaced by the ability to sample a very large chemical space to identify the ligand components of the capture agent. For example, an initial ligand binder (an anchor ligand) may be identified by screening the protein against a large (>10<sup>6</sup> element) one-bead-one-compound (OBOC)<sup>15</sup> peptide library, where the peptides themselves may be composed of natural, non-natural, and/or artificial amino acids. That anchor ligand is then utilized in an in situ click screen, again using a large OBOC library, to identify a biligand binder. A second advantage is that the process can be repeated, so that the biligand is used as an anchor to identify a triligand and so forth. The final capture agent can then be scaled up using relatively simple and largely automated chemistries and derivatized with biochemical handles, such as biotin, as an intrinsic part of its structure. The approach permits the exploration of branched, cyclic, and linear capture agent architectures. While many strategies for protein-directed multiligand assembly have been described,<sup>16,17</sup> most require detailed structural information on the target to guide the screening strategy, and most (such as the original in situ click approach) are optimized for low-diversity small molecule libraries.

Here we extend the use of iterative in situ click chemistry to synthesize a high-specificity branched, triligand capture agent/inhibitor for the Akt kinase. Akt is a critical molecular router that mediates signal transduction from the plasma membrane (cytokine receptors, GPCRs) to downstream effector molecules that control cell growth, apoptosis, and translation.<sup>18</sup> Akt overexpression and/or hyperactivation has been observed in numerous cancer types.<sup>19</sup> Such ubiquitous and aberrant Akt activity has made Akt a target for cancer diagnostics and therapeutics.<sup>20</sup> For developing a capture agent/inhibitor against Akt, we developed two novel screening strategies. First, we report on the use of a preinhibited form of the kinase as a screening target, which provides an approach toward developing an allosteric site inhibitor. Second, we take advantage of the fact that an in situ click screen, in which an anchor ligand and protein target are screened against a large OBOC library, will selectively generate triazole-linked products on the hit beads. We characterize the efficiency of this process through the use of a novel QPCR assay to quantify the on-bead product. We also expand this concept in the form of 'product screens', in which the presence of on-bead clicked product is taken to be the signature of a hit bead. We show that

such a product screen can be utilized to increase the affinity and/or selectivity of the final multiligand capture agent. Finally, we report on the affinity, selectivity, and inhibitory characteristics of the triligand capture agent/inhibitor, and we demonstrate its use in cell-based biological assays.

## EXPERIMENTAL SECTION

There are a number of affinity, selectivity, biochemical, and biological assays described in this work. Full experimental procedures, synthetic protocols, and additional experimental data are discussed in the Supporting Information.


Three different types of screens were employed for this work. The first screen, called a target screen, is analogous to most screening strategies described in the literature. Hit beads are identified by selecting those beads onto which the target protein has bound. The second type of screen, called an inhibited target screen, is based on selecting those beads on to which the target protein has bound, but the screen itself is carried out in the presence of a small molecule inhibitor. The third type of screen is the product screen; hit beads are identified by the presence of on-bead triazole-linked product.

**Screening: General.** All screens utilized OBOC peptide libraries that were synthesized on TentaGel (Rapp Polymere) using standard Fmoc SPPS protocols. Blocking conditions were carried out in Akt Blocking Buffer: 25 mM Tris-Cl (pH = 7.5), 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 0.1% (v/v) β-mercaptoethanol, 0.1% (v/v) Tween-20, and 1 mg/mL BSA. The results of each screen are presented in the Supporting Information.

**Screening: Anchor Ligand.** An initial anchor ligand against Akt was identified through the use of an inhibited target screen. The OBOC library was synthesized manually and was of the form H<sub>2</sub>N-AzX-XXXXX-GYM-TG where TG = TentaGel resin, X = one of eighteen natural L-amino acids (Cys, Met), and AzX = one of three azido amino acids Az2, Az4, and Az8 (Supporting Information, Figure S2). The syntheses of Az2 is described in the Supporting Information; the synthesis of Az4 and Az8 were carried out as previously described.<sup>11</sup> Inhibited Target Screen: The initial screen was carried out in the presence of 21 nM Akt1-S473E-T308P and 500 μM of the inhibitor Ac7 under blocking conditions for 75 min at room temperature. Binding was detected by probing with a monoclonal antibody specific for phosphorylated T308, followed by anti-mouse secondary antibodies conjugated with alkaline phosphatase. Purple "hit" beads (defined by color change in the presence of 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) substrate) were washed in water, stripped with 7.5 M Guad-Cl (pH = 2), and sequenced by Edman degradation (Supporting Information, Figure S3). The initial hit sequences defined a focused library which was subjected to an inhibited target screen as described above (Supporting Information, Figures S4 and S5). Candidate sequences were scaled up and tested for their ability to inhibit Akt1-S473E-T308P activity. The most potent sequence was resynthesized as a C-terminal biotinylated peptide and used as the anchor in the biligand screen (Scheme 1).

**Screening: Biligand Branch.** The biligand branch was identified through a two-step screening process of a target screen to identify potential hits, followed by a product screen of those hit beads to identify true hits. Target Screen: A naïve library of the form H<sub>2</sub>N-Pra-XXXXX-GM-TG where TG = TentaGel resin, X = one of eighteen natural L-amino acids (lacking Cys and Met), and Pra = L-propargylglycine was synthesized by standard split-mix protocols on a Titan 357 automated peptide synthesizer (AAPPTeC). The library was incubated with 90 μM biotinylated anchor peptide and either Akt1-S473E (9 nM) or Akt1-S473E-T308P (37 nM) under blocking conditions for 90 min at room temperature. Binding was detected by antibodies against the phosphorylated or nonphosphorylated form of Akt1. After color development,



Scheme 2. Strategy for Biligand Screens<sup>a</sup>

<sup>a</sup>A comprehensive pentapeptide library is synthesized on TentaGel (yellow circle) and appended with propargylglycine, an acetylene-containing amino acid. This library is incubated with the Akt1 kinase domain (grey) and biotinylated anchor peptide (black). The solid-phase library is probed with an anti-Akt antibody followed by a secondary antibody conjugated to alkaline phosphatase (purple). Hit beads are re-probed with the antibodies alone to eliminate antibody binders. The hit beads are washed, stripped, and re-probed with AlexaFluor647-labeled streptavidin (red) and imaged for fluorescence. The most highly fluorescent beads are sequenced to obtain the biligand candidates. The target screens resulted in hit frequencies between 0.001% and 0.01% of the beads in the naïve library while the product screen validated between 23% and 37% of these beads for sequencing.

ATP-binding pocket across kinases, and hence the often-observed poor selectivity of inhibitors targeted to such sites,<sup>28</sup> an approach toward developing off-site inhibitors may have unique advantages.

While the anchor peptide displayed excellent selectivity for Akt1-S473E, its affinity (>25  $\mu\text{M}$ ) was unsuitable for high-sensitivity capture of Akt. To increase the affinity, a biligand branch was selected through a sequence of target and product screens (Scheme 2). For these screens, the anchor peptide was modified with a C-terminal biotin for use in the product screen. We hypothesized that the combination of an initial target screen, followed by a product screen of those initial hit beads, would identify only the library members that bound the target and participated in a successful click event. The target screens resulted in hit frequencies between 0.001% and 0.01% of the beads in the naïve library. The product screen with fluorescent streptavidin validated between 23% and 37% of these beads for sequencing.

The sequences obtained in the secondary ligand screen showed a preference for aromatic amino acids in the first three random positions (Supporting Information, Figure S8). We selected three peptide sequences and synthesized the corresponding biligands with the 1,4-triazole using the Cu(I)-catalyzed azide–alkyne cycloaddition.<sup>29,30</sup> Two of the three showed increased binding to Akt1 in immunoprecipitation experiments, and the most promising candidate (Ac-Pra-FWFLRG-CONH<sub>2</sub>, Pra = propargylglycine) was scaled up for additional characterization and for the development of the triligand.


For triligand development, the selected biligand was appended with 5-hexynoic acid at the N-terminus and used as the anchor ligand (Supporting Information, Figure S9). We omitted the target screen in these experiments, electing to employ only the product screen for triazole formation. Results from the naïve library revealed weak consensus for the tertiary peptide, although Az8 was the preferred amino acid at position 1, and positions 2, 3, and 4 showed a propensity for positively charged amino acids (Supporting Information, Figure S10). We designed a focused library based on the amino acid frequencies observed in the initial screen and identified a tertiary ligand consensus sequence with

positively charged amino acids at positions 2 and 4, negatively charged amino acids at position 3, and hydrophobic amino acids at position 5 (Supporting Information, Figure S11). From this pool, we selected the tertiary peptide Ac-Az8-RHERI-CONH<sub>2</sub> and conjugated it to the biligand to form a biotinylated branched triligand (Figure 3A).

**Characterizing the On-Bead in Situ Click Reaction.** The target screen is an important and unique aspect of the methodologies reported here. Thus, we sought to determine the efficiency and selectivity of the in situ click reaction between the on-bead secondary peptide and the soluble anchor peptide in the presence and absence of Akt1-S473E. Previous work in our laboratory<sup>11</sup> suggested that the in situ reaction is low-yielding relative to the Cu(I)-catalyzed process. Thus, we developed an analytical assay based on immuno-PCR<sup>31</sup> as a means of amplifying and detecting the in situ product. This method takes advantage of the exquisite sensitivity and large dynamic range of quantitative PCR (QPCR). We carried out variations of the in situ click reaction between the biotinylated anchor peptide and resin-bound secondary peptides. We then used the biotin label to attach a streptavidin–oligonucleotide (SA-oligo) onto only those beads that contained biligand product. In order to account for variable sizes, five beads were individually selected and added to each QPCR reaction, the threshold cycle (Ct) was determined for each reaction condition, and a standard curve was used to calculate the amount of biligand present on the bead for each reaction condition (Figure 1). The click reaction between the two peptides was approximately 10-fold more efficient in the presence of Akt1 than in its absence, confirming the requirement for the target protein to catalyze the click reaction. When the anchor peptide was immobilized and the biotinylated secondary peptide was in solution, the efficiency of the in situ click process was reduced by a factor of 4 (but still above background level), suggesting that the in situ click reaction observed in the screen is dependent on the identities of the anchor and secondary peptides and the manner in which they are displayed (on-bead or in solution). The copper catalyzed click reaction did not display any orientation dependence, providing further evidence that the click reaction observed in the screening process is highly target-dependent.


The biligand branch was selected in the context of an 8-carbon linker between the two peptide ligands. We assayed for the selectivity of the in situ click screen by measuring the inhibition characteristics of biligands prepared with 1, 4, or 8 carbon atom linkers, but otherwise identical peptide components (Figure 2A). We found that the selected biligand with the longest linker ( $n = 8$ ) possessed a significantly higher inhibitory potency (Figure 2B) relative to  $n = 4$  and  $n = 1$  linkers. This again suggests that the secondary peptide was selected in the context of spatial constraints that define the protein–peptide interactions. We note that only multiligands linked by 1–4 triazoles (anti) were synthesized. The in situ reaction can result in formation of both the 1–4 (anti) and 1–5 (syn) triazole. It is possible that the 1–5 triazole (syn) may be the favored linkage and may confer additional affinity and/or selectivity to the multiligand. However, on the basis of the fact that our linker between the separate peptide ligands is a flexible eight-carbon bridge, we would not expect a significant difference between the two triazole isomers.

Taken together, these experiments suggest that the “hit” sequences that emerged from our biligand screens were determined by (1) the target protein, (2) the soluble anchor peptide, and (3) the relative spacing between the azide and acetylene



**Figure 1.** Determination of on-bead in situ click reaction efficiency. (A) The secondary ligand (red letters) is synthesized on TentaGel (yellow) with an N-terminal propargylglycine and the soluble anchor peptide is appended with a C-terminal biotin (black) and an N-terminal azido-amino acid (Az8). These are incubated together under conditions described below. After the reaction is completed, the beads are washed, stripped, and probed with a streptavidin–oligonucleotide template (SA-Oligo) (red) to detect the formation of the triazole. The beads were then subjected to on-bead QPCR. (B) Results of QPCR. The reaction conditions were (1) Akt1 + biotinylated anchor peptide + bead, (2) biotinylated anchor peptide + bead, (3) bead, and (4) CuI/ascorbic acid + biotinylated anchor peptide + bead. The red bars represent the reaction configuration described in panel a; the black bars represent reactions where the anchor peptide is synthesized on bead and the biotinylated secondary peptide is in solution (inverted configuration). The error bars represent standard error. In this experiment, the efficiency of the on-bead in situ click reaction is approximately 10-fold higher in the presence of the Akt1 target than in its absence. For comparison, the efficiency of the Cu(I)-catalyzed click reaction is approximately 3 orders of magnitude higher than the protein-templated reaction. (C) Standard curve of SA-oligo template: Each point is the mean Ct of duplicate experiments.


functionalities in each component. Because the signal-to-noise ratio of the in situ screen (true hit/false positive) depends on the relative rates of the target-mediated and background reactions, QPCR-guided optimization of the screening conditions may significantly increase the robustness of the sequential in situ click approach. In contrast to previous work with small molecule biligands,<sup>12,32,33</sup> we expect the high conformational entropy of the anchor and secondary peptides to result in a smaller population of ternary complexes with the correct conformational and geometrical orientation required by the cycloaddition reaction.



**Figure 2.** Effect of biligand linker length on Akt inhibition. (A) Biligands were synthesized with one-, four-, and eight-carbon linkers between the anchor peptide and triazole. (B) Each variant was titrated against activated Akt1-S473E-T308P, the activity was measured by immunoblotting and quantitated by densitometry. The  $n = 8$  linker which was present in the screen clearly yields the biligand with the highest inhibitory potency.

The use of long, conformationally restricted linkers in the anchor and library peptides, or perhaps the use of N-methylated amino acids<sup>34</sup> in the OBOC libraries, may reduce this effect and capture more of the individual binding energies in the biligand product.

**Affinity and Specificity Characterization of Multiligand PCC Agents.** We tested the affinity of the anchor, biligand, and triligand by ELISA with immobilized Akt-S473E (Figure 3B). As a detection agent, the biligand showed >100-fold improvement in its affinity for Akt relative to the anchor peptide while the triligand showed only a modest affinity gain (2–3 fold). When the triligand is employed as an immobilized capture agent, analysis by surface plasmon resonance (SPR) confirms mid- to low-nanomolar affinity for Akt1-S473E ( $K_D = 200$  nM, Figure 3C). We next sought to address the specificity of the triligand for a panel of His-tagged protein kinases (Figure 3D). For these assays, the multiligands were used as immobilized capture agents for Akt1-S473E as well as a set of commercially available active, His-tagged protein kinase domains from the AGC family (Akt1, PDK1, and p70s6 kinase), the STE family (MEK1), and the GMGC family (GSK3 $\beta$ ). The relative affinity of each kinase was determined by probing with a horseradish peroxidase-conjugated anti-His6 antibody and normalizing the response to Akt1-S473E. The anchor was very specific for the Akt1 protein, with only modest binding to GSK3 $\beta$ . The significantly higher affinity biligand showed reduced selectivity, with significant cross-reactivity to GSK3 $\beta$ . For the triligand, however, binding to GSK3 $\beta$  was significantly reduced, bringing it close to the level observed for the anchor peptide. Additionally, the off-target binding to MEK1 is completely eliminated at the triligand



**Figure 3.** Characterization of Akt triligand. (A) Structure of the biotinylated Akt triligand. (B) Relative affinity of Akt triligand and its components. Akt-S473E was immobilized on Ni-NTA plates and incubated with varying concentrations of biotinylated peptide. All values were normalized to the binding observed at saturation. (C) Absolute affinity of the triligand by surface plasmon resonance. For this experiment, the biotinylated triligand was immobilized on a streptavidin-derivatized Biacore chip and probed with Akt-S473E. Fits for the sensograms are shown as solid lines, and the  $K_D$  was found to be 200 nM by determination of the kinetic parameters. (D) Specificity of anchor, biligand, and triligand. Biotinylated ligand was immobilized on streptavidin plates and probed with an array of His-tagged kinases. Values represent the mean A450 obtained from three experiments after normalization to Akt1-S473E binding. The error bars show the standard error. Note that although the affinity of the triligand is only marginally improved over the biligand, the selectivity for Akt1 is clearly enhanced.

stage. To quantify the changes in selectivity for Akt1 and GSK3 $\beta$ , we carried out a similar ELISA-based binding analysis using a range of kinase concentrations (Supporting Information, Figure S18). As we translate from biligand to triligand, the affinity for Akt1 increases modestly while the affinity for GSK3 $\beta$  is decreased by approximately 2-fold. This demonstrates that Akt1 specificity, which is lost at the biligand stage, is partially regained at the triligand stage, mainly through destabilizing interactions with GSK3 $\beta$ .


The biligand exhibited a significant affinity enhancement for Akt1, but also a reduced selectivity when assayed against off-target kinases. The triligand, by contrast, exhibited only a modest affinity improvement but a significant selectivity enhancement relative to the biligand. These observations suggest that large increases in affinity may come at the cost of reduced specificity, but the increased specificity need not be accompanied by increased affinity. This is consistent with previous studies on antibody–small molecule interactions,<sup>35</sup> DNA–protein interactions,<sup>36</sup> and protein–protein interactions.<sup>37–39</sup> Indeed, a recent study demonstrated an inverse correlation between affinity and selectivity for small molecule protein kinase inhibitors.<sup>40</sup> For the case of the capture agents reported here, the tertiary peptide contributes destabilizing interactions to GSK3 $\beta$  while making only marginal stabilizing interactions to Akt1. This suggests that the in situ click

product screen approach described here has the potential to increase the specificity of the multiligand in a manner reminiscent of negative design.<sup>41</sup> This makes intuitive sense. Unlike most screening methodologies, the product screening strategy employed here does not define hits as those that bind the protein most strongly, but instead it defines hits as those that are compatible with the protein-catalyzed process.

**Triligand Inhibition of Akt1.** We carried out two standard enzyme kinetic assays to determine the mode of Akt1 inhibition by the triligand.<sup>42</sup> For such assays, the kinase activity is measured under varying substrate and triligand concentrations (Figure 4). The resulting data can be interpreted so that the nature of the competition between the triligand and the substrate for the relevant kinase binding site is determined. For example, if the triligand and ATP competed for the same binding pocket, the maximum velocity ( $V_{max}$ ) of the kinase would be unchanged while the Michaelis constant ( $K_M$ ) would increase. The plots can also be used as a means of determining the inhibition constant ( $K_i$ ) of the triligand. The results (Figure 4) show reduction in the enzyme  $V_{max}$  for both substrates, as a function of increasing triligand concentration. This indicates that the triligand does not directly compete with either substrate for binding to their respective binding sites. When ATP is the varied substrate, triligand addition appears to have no effect on  $K_M$ , consistent

with noncompetitive inhibition. When the peptide concentration is varied,  $K_M$  decreases in a manner consistent with uncompetitive inhibition. However, when inhibition constants are determined from the Dixon plot (varied [ATP]) and the Cornish–Bowden plot (varied [peptide]), the similarity in values ( $4 \mu\text{M}$  vs  $2.6 \mu\text{M}$ , respectively, Table 1) suggests that triligand inhibition occurs in a noncompetitive fashion. Regardless of the exact mechanism, these experiments rule out competitive inhibition with respect to the ATP and peptide substrates.

The competitive enzyme kinetics studies demonstrate that the triligand binds to a site distinct from the active (ATP or peptide-binding) site of the kinase and so achieves its inhibitory characteristics via an allosteric mechanism. This supports our hypothesis that blocking the ATP-binding site with Ac7 enabled the library to sample alternate binding sites with unexpected functional properties. While the precise mechanism for inhibition is unknown, competition ELISA experiments suggest that the multiligand binding site may partially overlap with that of an anti-Akt1 antibody directed toward the C-terminus (Supporting Information, Figure S17). The C-terminus is effectively on the ‘backside’ of the kinase domain, opposite the active site.



**Figure 4.** Inhibition of Akt1 activity. (A) Velocity vs [peptide substrate] with varying concentration of inhibitory triligand. (B) Velocity vs [ATP] with varying concentration of inhibitory triligand. In both experiments, the  $V_{\max}$  of Akt1 is decreasing as the [triligand] increases, evidence that the triligand is not competing with either substrate. The figures to the right of each graph illustrate the conclusion that the triligand was not competitive with respect to either the peptide or ATP binding site.


**Biological Applications of the Branched Triligand.** The ultimate test of a protein capture agent is whether or not it can be used to detect its cognate protein from a biologically relevant sample. We tested whether the multiligand capture agents could recognize full-length Akt from cancer cell lines. Previous studies have shown that Akt2 is overexpressed in the OVCAR3 ovarian cancer cell line, and so we utilized this cell line as an experimental platform for immunoprecipitation (IP) and immunocytochemical experiments (ICC).<sup>43</sup> For the IP experiments, we immobilized the anchor, biligand, and triligand on streptavidin-agarose and panned each resin with OVCAR3 cell lysates obtained from cells stimulated with a combination of epidermal growth factor (EGF) and insulin or from untreated cells (Figure 5A). Probing the elutions with pan-Akt antibody, which detects all three isoforms of Akt, confirms the increased affinity of the biligand relative to the anchor peptide in lysates from both induced and noninduced cells. The triligand shows somewhat increased immunoprecipitation of Akt relative to the biligand in induced cell lysates but not in the noninduced control cell lysate. This effect is also observed when the immunoprecipitations are probed with an antibody specific for Akt phosphorylated Ser473 (Ser474 in Akt2). Analysis of the total immunoprecipitated protein by SDS-PAGE showed low nonselective binding for all the ligands (Supporting Information, Figure S15). A protein at approximately 50 kDa is immunoprecipitated by the triligand and, to a lesser extent, by the anchor and biligand. On the basis of our characterization of triligand specificity, this likely corresponds to the GSK3 kinase which has a predicted molecular weight of 47 kDa. We are currently investigating the basis for off-target GSK3 binding which is particularly surprising given the low sequence homology between Akt1 and GSK3.

These experiments confirm the increase in capture efficiency as the combined affinity/selectivity metrics of the capture agent are increased by translating from anchor to biligand to triligand, particularly in cells stimulated through the PI3K pathway by insulin and EGF. We compared the performance of our capture agent against an antibody that was similarly raised against the kinase domain of Akt1 (Figure 5A, lane 5) for an ‘apples to apples’ comparison of immunoprecipitation efficiency. Interestingly, the commercial anti-Akt1 antibody shows almost no immunoprecipitation of Akt. The poor performance of the antibody may be due to nonoptimal presentation on streptavidin–agarose, or some other experimental artifact, but that poor performance was observed across many assays and across multiple batches of antibody. Even for an equivalently performing antibody, the ability to use large amounts of triligand at relatively

**Table 1.** Kinetic Parameters from Competition Experiments<sup>a</sup>

	V vs [peptide], variable [triligand]	V vs [ATP], variable [triligand]
$K_M$ ( $\mu\text{M}$ ) (this work)	$9 \pm 0.7$ (peptide)	$213 \pm 25$ (ATP)
$K_M$ ( $\mu\text{M}$ ) (literature)	$3.5$ (peptide)	$155$ (ATP)
$V_{\max}$ (pmol/min/mg)	$45764 \pm 1486$	$98996 \pm 8242$
$K_i(K'_i)$ ( $\mu\text{M}$ )	$(2.6 \pm 0.7)$	$4 \pm 1$
inhibition mode	uncompetitive	noncompetitive

<sup>a</sup>  $K_M$  and  $V_{\max}$  values for Akt1-S473E-T308P were obtained by nonlinear regression from the results of the inhibition experiments described above (GraphPad). The literature values for the Michaelis constants for ATP and substrate peptide were taken from Klein et. al.<sup>21</sup> The triligand  $K_i$  (noncompetitive inhibition) was obtained from the negative X-intercept of the Dixon plot of  $1/v$  vs [triligand] with varying [ATP]. The  $K_i$  is the mean value of the observed X-intercepts, and the error range is the standard deviation. The triligand  $K'_i$  (uncompetitive inhibition) was obtained from the intercept of the Cornish–Bowden plot of [peptide]/v vs [triligand] with varying [peptide]. The  $K'_i$  is the mean value of the intercepts, and the error range is the standard deviation. These plots as well as additional kinetic analyses are presented in Supporting Information Figures S12 and S13.



**Figure 5.** Immunoprecipitation and immunocytochemical experiments with OVCAR3 cells. (A) Biotinylated ligands were immobilized on streptavidin–agarose and incubated with lysates from OVCAR3 cell lines treated with EGF and insulin (induced) or untreated (control). After 18 h at 4 °C, resins were washed exhaustively, eluted with SDS-PAGE sample buffer, and analyzed by Western blotting. (1) Blank resin, (2) anchor, (3) biligand, (4) triligand, (5) [5G3] mAb, (L) lysate. (B) Immunofluorescent images of Akt in fixed OVCAR3 cells stained with either a fluorescein-conjugated anti-AKT antibody (Ab) or a fluorescein-conjugated triligand (TL). Each imaging agent distinguishes cytoplasmic or membrane-bound AKT in unstimulated or EGF+insulin-treated cells, respectively. Contrast is enhanced equally in all images, but the fluorescence images of the triligand stained cells were achieved at a 3-fold lower excitation laser intensity relative to the (much dimmer) antibody-stained cells. Scale bar = 100  $\mu$ m.

low cost relative to a monoclonal antibody confers a significant advantage.

To further explore the interaction between the multiligand capture agent and full-length Akt, we synthesized a fluorescein-labeled triligand (Supporting Information, Figure S16) and employed it as an ICC imaging agent in fixed, permeabilized OVCAR3 cells. This construct was benchmarked against a fluorescein-labeled monoclonal antibody specific for Akt. For this assay, Akt is expected to locate to the cell membrane following stimulation of receptor tyrosine kinases by EGF and insulin. Images of unstimulated and stimulated cells clearly reveal this effect (Figure 5B). Both compounds show localization of Akt at the plasma membrane after cell stimulation, presumably mediated through binding of the pleckstrin homology domain (PHD) to phosphatidylinositol (3,4,5)-trisphosphate at the inner face of the membrane.

## CONCLUSIONS

In this work we have demonstrated the design of a peptide-based drop-in replacement for Akt monoclonal antibodies using

iterative on-bead in situ click chemistry. The triligand can function as both a capture and detection agent in standard ELISA and biological assays. The allosteric inhibitory properties of the triligand highlight an additional therapeutic potential of these novel capture agents that we are currently investigating.

## ASSOCIATED CONTENT

**S Supporting Information.** Full citations for references 6 and 28, synthetic protocols, compound characterization, experimental protocols, and additional data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

### Corresponding Author

heath@caltech.edu

### Present Addresses

<sup>||</sup>School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, California, 95343, United States.

## ACKNOWLEDGMENT

This work was supported by the National Cancer Institute grant No. 5U54CA119347 (J.R.H., P.I.), the Institute for Collaborative Biotechnologies (contract no. W911NF-09-D-0001 from the U.S. Army Research Office), The Institute of Bioengineering and Nanotechnology (Biomedical Research Council, Agency for Science, Technology and Research, Singapore), and the Grand Duchy of Luxembourg via a subcontract from the Institute for Systems Biology. S.W.M. acknowledges support from an NRSF postdoctoral fellowship 1F32CA136150-01. We thank Prof. Carl Parker for the generous use of his equipment and expertise. The Akt1-S473E plasmid was a gift from Dr. Shoshana Klein (The Hebrew University of Jerusalem). Expression of the Akt1-S473E was carried out by the Protein Expression Center at Caltech.

## REFERENCES

- (1) Borrebaeck, C. A. K. *Immunol. Today* **2000**, *21*, 379.
- (2) Kodadek, T.; Reddy, M. M.; Olivos, H. J.; Bachhawat-Sikder, K.; Alluri, P. G. *Acc. Chem. Res.* **2004**, *37*, 711.
- (3) Kijanka, G.; Ipcho, S.; Baars, S.; Chen, H.; Hadley, K.; Beveridge, A.; Gould, E.; Murphy, D. J. *Immunol. Methods* **2009**, *340*, 132.
- (4) Michaud, G. A.; Salcius, M.; Zhou, F.; Bangham, R.; Bonin, J.; Guo, H.; Snyder, M.; Predki, P. F.; Schweitzer, B. I. *Nat. Biotechnol.* **2003**, *21*, 1509.
- (5) Smith, G. P.; Petrenko, V. A. *Chem. Rev.* **1997**, *97*, 391.
- (6) Gold, L.; et al. *PLoS One* **2010**, *5*, e15004.
- (7) Ostroff, R. M.; Bigbee, W. L.; Franklin, W.; Gold, L.; Mehan, M.; Miller, Y. E.; Pass, H. L.; Rom, W. N.; Siegfried, J. M.; Stewart, A.; Walker, J. J.; Weissfeld, J. L.; Williams, S.; Zichi, D.; Brody, E. N. *PLoS One* **2010**, *5*, e15003.
- (8) Xu, J. L.; Davis, M. M. *Immunity* **2000**, *13*, 37.
- (9) Zemlin, M.; Klinger, M.; Link, J.; Zemlin, C.; Bauer, K.; Engler, J. A.; Schroeder, H. W., Jr.; Kirkham, P. M. *J. Mol. Biol.* **2003**, *334*, 733.
- (10) Chothia, C.; Lesk, A. M.; Tramontano, A.; Levitt, M.; Smith-Gill, S. J.; Air, G.; Sheriff, S.; Padlan, E. A.; Davies, D.; Tulip, W. R.; et al. *Nature* **1989**, *342*, 877.
- (11) Agnew, H. D.; Rohde, R. D.; Millward, S. W.; Nag, A.; Yeo, W. S.; Hein, J. E.; Pitram, S. M.; Tariq, A. A.; Burns, V. M.; Krom, R. J.; Fokin, V. V.; Sharpless, K. B.; Heath, J. R. *Angew. Chem., Int. Ed.* **2009**, *48*, 4944.

- (12) Manetsch, R.; Krasinski, A.; Radic, Z.; Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. *J. Am. Chem. Soc.* **2004**, *126*, 12809.
- (13) Jencks, W. P. *Proc. Natl. Acad. Sci. U.S.A.* **1981**, *78*, 4046.
- (14) Murray, C. W.; Verdonk, M. L. *J. Comput.-Aided Mol. Des.* **2002**, *16*, 741.
- (15) Lam, K. S.; Salmon, S. E.; Hersh, E. M.; Hruby, V. J.; Kazmierski, W. M.; Knapp, R. J. *Nature* **1991**, *354*, 82.
- (16) Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 9367.
- (17) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. *Science* **1996**, *274*, 1531.
- (18) Vivanco, I.; Sawyers, C. L. *Nat. Rev. Cancer* **2002**, *2*, 489.
- (19) Altomare, D. A.; Testa, J. R. *Oncogene* **2005**, *24*, 7455.
- (20) Garcia-Echeverria, C.; Sellers, W. R. *Oncogene* **2008**, *27*, 5511.
- (21) Klein, S.; Geiger, T.; Linchevski, L.; Lebendiker, M.; Itkin, A.; Assayag, K.; Levitzki, A. *Protein Expr. Purif.* **2005**, *41*, 162.
- (22) Meyer, S. C.; Shomin, C. D.; Gaj, T.; Ghosh, I. *J. Am. Chem. Soc.* **2007**, *129*, 13812.
- (23) Shomin, C. D.; Meyer, S. C.; Ghosh, I. *Bioorg. Med. Chem.* **2009**, *17*, 6196.
- (24) Obata, T.; Yaffe, M. B.; Leparo, G. G.; Piro, E. T.; Maegawa, H.; Kashiwagi, A.; Kikkawa, R.; Cantley, L. C. *J. Biol. Chem.* **2000**, *275*, 36108.
- (25) Souroujon, M. C.; Mochly-Rosen, D. *Nat. Biotechnol.* **1998**, *16*, 919.
- (26) Samson, I.; Kerremans, L.; Rozenski, J.; Samyn, B.; Van Beeumen, J.; Van Aerschot, A.; Herdewijn, P. *Bioorg. Med. Chem.* **1995**, *3*, 257.
- (27) Kirkland, L. O.; McInnes, C. *Biochem. Pharmacol.* **2009**, *77*, 1561.
- (28) Karaman, M. W.; et al. *Nat. Biotechnol.* **2008**, *26*, 127.
- (29) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2002**, *41*, 2596.
- (30) Tornøe, C. W.; Christensen, C.; Meldal, M. *J. Org. Chem.* **2002**, *67*, 3057.
- (31) Niemeyer, C. M.; Adler, M.; Wacker, R. *Trends Biotechnol.* **2005**, *23*, 208.
- (32) Mocharla, V. P.; Colasson, B.; Lee, L. V.; Roper, S.; Sharpless, K. B.; Wong, C. H.; Kolb, H. C. *Angew. Chem., Int. Ed.* **2004**, *44*, 116.
- (33) Whiting, M.; Muldoon, J.; Lin, Y. C.; Silverman, S. M.; Lindstrom, W.; Olson, A. J.; Kolb, H. C.; Finn, M. G.; Sharpless, K. B.; Elder, J. H.; Fokin, V. V. *Angew. Chem., Int. Ed.* **2006**, *45*, 1435.
- (34) Chatterjee, J.; Gilon, C.; Hoffman, A.; Kessler, H. *Acc. Chem. Res.* **2008**, *41*, 1331.
- (35) Schildbach, J. F.; Panka, D. J.; Parks, D. R.; Jager, G. C.; Novotny, J.; Herzenberg, L. A.; Mudgett-Hunter, M.; Brucoleri, R. E.; Haber, E.; Margolies, M. N. *J. Biol. Chem.* **1991**, *266*, 4640.
- (36) Jen-Jacobson, L. *Biopolymers* **1997**, *44*, 153.
- (37) Nguyen, J. T.; Porter, M.; Amoui, M.; Miller, W. T.; Zuckermann, R. N.; Lim, W. A. *Chem. Biol.* **2000**, *7*, 463.
- (38) Nguyen, J. T.; Turck, C. W.; Cohen, F. E.; Zuckermann, R. N.; Lim, W. A. *Science* **1998**, *282*, 2088.
- (39) Zarrinpar, A.; Park, S. H.; Lim, W. A. *Nature* **2003**, *426*, 676.
- (40) Posy, S. L.; Hermsmeier, M. A.; Vaccaro, W.; Ott, K.-H.; Todderud, G.; Lippy, J. S.; Trainor, G. L.; Loughney, D. A.; Johnson, S. R. *J. Med. Chem.* **2011**, *54*, 54.
- (41) Mason, J. M.; Muller, K. M.; Arndt, K. M. *Biochemistry* **2007**, *46*, 4804.
- (42) Segel, I. H. *Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems*; Wiley: New York, 1975.
- (43) Yang, L.; Dan, H. C.; Sun, M.; Liu, Q.; Sun, X. M.; Feldman, R. I.; Hamilton, A. D.; Polokoff, M.; Nicosia, S. V.; Herlyn, M.; Sebt, S. M.; Cheng, J. Q. *Cancer Res.* **2004**, *64*, 4394.